Shots:
- LENZ has entered into an exclusive license & commercialization agreement with Arrotex to register & commercialize Vizz (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in Australia & New Zealand
- As per the deal, Arrotex will obtain exclusive commercialization rights for Vizz for the treatment of presbyopia in Australia & New Zealand. In return, LENZ will receive an upfront payment & a profit share of gross margin from product sales
- Vizz (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop that restores clear near vision for up to 10 hours, with rapid and durable efficacy
Ref: Globenewswire | Image: LENZ & Arrotex | Press Release
Related News: CStone Pharmaceuticals Partners with Arrotex to Commercialize Sugemalimab across Australia and New Zealand
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
